Improvement in the Appearance of Periorbital Wrinkles

Goldman, Butterwick, Fitzpatrick and Groff

Status and phase

Unknown

Phase 3

Conditions

Periorbital Wrinkles

Treatments

Drug: enhanced DefenAge 8-in-1 BioSerum

Study type

Interventional

Funder types

Other

Identifiers

NCT05082766

DefenAge-2021-01

Details and patient eligibility

About

The primary objective of this study is to evaluate the efficacy of DefenAge 8-in-1 BioSerum supplemented with the enhanced concentration of defensins (enhanced 8-in-1 BioSerum) in the improvement of periorbital wrinkles.

Full description

Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the face including periorbital area.

Subjects satisfying all inclusion and exclusion criteria will be enrolled in this trial. Prior to receiving any study treatment, mandatory photography using Canfield Vectra 3D and VISIA. Patients will return for follow-up assessments at Day 30, 60, and 90.

Enrollment

20 estimated patients

Sex

All

Ages

31+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female subjects in general good health greater than 30 years of age
Must be willing and capable of giving consent and signing an Informed Consent Form
Subjects with moderate to severe periorbital wrinkles (at least a grade II in wrinkles and score of 4 in elastosis on the Fitzpatrick-Goldman wrinkle scale)
Female Subjects will be either of non-childbearing potential defined as:
1. Having no uterus
2. No menses for at least 12 months
3. Bilateral tubal ligation Or; (WOCBP) women of childbearing potential, must have had a regular menstrual cycle prior to study entry. All systemic birth control measures must be in consistent use at least 6 months prior to study participation. WOCBP must agree to use an effective method of birth control during the course of the study, such as:

1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
2. Intrauterine coil
3. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
4. Abstinence or same sex partner (If practicing abstinence or sexual activity with a same sex partner, must agree to use barrier method described above (c) if becomes sexually active with a non-vasectomized male partner).
5. Vasectomized male partner (for at least 6 months) (must agree to use barrier method described above (c) if becomes sexually active with un-vasectomized male partner).
Negative urine pregnancy test results at Baseline prior to study entry (if applicable)

Exclusion criteria

History of sensitivity to any ingredient in DefenAge 8-in-1 BioSerum.
Subjects receiving any topical cosmetic anti-wrinkle and/or skin lightening products known to affect skin aging such as products containing hydroquinone, vitamin A derivatives (retinol, tretinoin, adapalene, tazarotene), alpha/beta/poly-hydroxy acids (salicylic acid, glycolic acid etc.), vitamins C or D (includes derivatives thereof), arbutin, retinol, azelaic acid, kojic acid, licorice extracts, bearberry extracts, mequinol) on the treatment area within 14 days prior to or during the study period, other than the study product.
Subjects using any topical imiquimod, 5-fluorouracil, or diclofenac on their face within 12 weeks prior to or during the study period
Subjects who have had a microdermabrasion (light or medium skin peel on their face within 30 days prior to or during the study period
Subjects receiving a chemical peel, a non-ablative laser, light, radiofrequency, or ultrasound treatment on their face must have discontinued the drug/treatment at least 3 months prior to entering the study
Subjects receiving Dermabrasion (deep skin peel) and/or ablative laser treatments on their face, and systemic retinoids must have discontinued the drug/treatment at least 6 months prior to entering the study
History of or the presence of any skin condition/disease that might, in the opinion of the investigator, interfere with the diagnosis or evaluation of study parameters (i.e., acne, atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)
Subjects with current actinic keratoses or any other skin cancer(s) in the treatment areas
Subjects with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
Subjects with any active systemic disease that is not yet deemed medically stabilized
Subjects with an active bacterial, fungal, or viral infection
Subjects participating or completing participation in a clinical trial within 30 days prior to or during the study period
A female subject who is currently breast-feeding, nursing, pregnant or planning to becoming pregnant during the study period
Subjects not willing to comply with study dosing and complete the entire course of the study
Subjects not willing to avoid extended periods of sun exposure for the duration of the study (including tanning beds). During the study, when excessive sun exposure is unavoidable, subjects should wear appropriate protective clothing and use the dispersed sunscreen
Subjects who have had treatment with neuromodulators (ex. Botox, Dysport, or Xeomin) anywhere on the face within 6 months prior to or during the study period.
1. Subjects who have had treatment with fillers anywhere on the face, or other forms of facial soft tissue augmentation (ex. Fat transfer) within 6 months prior to or during the study period.